

RESEARCH REPORT



MOLECULAR DIAGNOSTICS FOR CANCER.
MARKETS FORECASTS BY CANCER TYPE, PRODUCT AND PLACE
WITH EXECUTIVE AND CONSULTANT GUIDES AND
CUSTOMIZATION.
2023 TO 2027





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides	19
1.1	Cancer MDx - Strategic Situation Analysis	20
1.2	Guide for Executives, Marketing, and Business Development Staff	23
1.3	Guide for Management Consultants and Investment Advisors.....	25
2	Introduction and Market Definition	26
2.1	What are Molecular Diagnostics?	27
2.2	The Diagnostics Revolution.....	27
2.3	Market Definition	29
2.3.1	Revenue Market Size.....	29
2.4	Methodology.....	31
2.4.1	Methodology	31
2.4.2	Sources	31
2.4.3	Authors	31
2.5	Perspective: Healthcare and the IVD Industry	33
2.5.1	Global Healthcare Spending	33
2.5.2	Spending on Diagnostics	34
2.5.3	Important Role of Insurance for Diagnostics	35
3	Market Overview.....	36
3.1	Market Segments	37
3.1.1	Traditional Market Segmentation.....	37
3.1.2	Laboratory Focus and Segmentation.....	38
3.2	Industry Structure.....	40
3.2.1	Hospital Testing Share	40
3.2.2	Economies of Scale.....	40
3.2.3	Physician Office Lab's.....	42

3.2.4	Physician's and POCT	42
4	Market Trends	43
4.1	Factors Driving Growth	44
4.1.1	New Diagnostics Create New Markets.....	44
4.1.2	New Roles for Diagnostics.....	45
4.1.3	The Aging Effect	45
4.1.4	Expanding the Pharmaceutical Toolbox.....	47
4.1.5	Regulatory Retreat	47
4.2	Factors Limiting Growth	48
4.2.1	Falling Prices.....	48
4.2.2	Lower Costs.....	49
4.2.3	Wellness has a Downside	49
4.3	Instrumentation, Automation and Diagnostic Trends	50
4.3.1	Traditional Automation and Centralization.....	50
4.3.2	The New Automation, Decentralization and Point Of Care	50
4.3.3	Instruments Key to Market Share	52
4.3.4	Bioinformatics Plays a Role	52
4.3.5	PCR Takes Command	52
4.3.6	Next Generation Sequencing Fuels a Revolution.....	53
4.3.7	NGS Impact on Pricing.....	54
4.3.8	Whole Genome Sequencing, A Brave New World	54
4.3.9	Companion Diagnostics Blurs Diagnosis and Treatment	54
4.3.10	Shifting Role of Diagnostics.....	55
4.3.11	Multiplexing and Foundation One	57
4.3.12	Pharmacogenomics Technology	57
4.3.13	Gene Editing and Gene Therapy.....	58
5	Molecular Diagnostics Recent Developments	59
5.1	Recent Developments – Importance and How to Use This Section	60

5.1.1	Importance of These Developments	60
5.1.2	How to Use This Section.....	60
5.2	Sema4 Exiting Reproductive Health Screening	60
5.3	Thermo Fisher Introduces Cancer Profiling Assay	61
5.4	Genomic Test IDs Cysts Likely to Progress to Cancer	63
5.5	Naveris to Commercialize Virus-Related Cancer Tests	66
5.6	Larger Liquid Biopsy Panels Loom.....	66
5.7	Halo Diagnostics to Offer Genomic Profiling Tests	72
5.8	BillionToOne Raises \$125M.....	73
5.9	Local Cancer Genomic Profiling Options Grow.....	73
5.10	German MDx Firm Mainz Biomed Raises \$10M in IPO	79
5.11	Guardant Health Q3 Revenues Up 27 Percent	80
5.12	BforCure Raises \$2.3M to Adapt Rapid PCR Platform for Cancer Detection.....	81
5.13	Nucleix to Invest in Early-Stage Lung Cancer Dx.....	82
5.14	Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics.....	84
5.15	Grail Gets Approval for Galleri Multicancer Test	85
5.16	Finnish Firms to Form Point-of-Care Testing Firm	85
5.17	Datar Cancer Genetics Expands to Dx and Screening.....	86
5.18	HTG Molecular Diagnostics: HTG Transcriptome Panel.....	90
5.19	PacBio's Omniome Acquisition Shortens Path to Clinical	91
5.20	Invitae to Acquire Genosity for \$200M	93
5.21	Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test	94
5.22	Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience.....	95
5.23	Natera Revenues Grow 35 Percent	96
5.24	AnchorDx Closes \$40M Financing Round	96
5.25	Exact Sciences Strategy for End-to-End Cancer Testing	97
5.26	Genomics England: Whole Genome Sequencing for Cancer Patients to Launch..	100

6	Profiles of Key MDx Companies	104
6.1	10x Genomics, Inc.....	105
6.2	Abbott Laboratories.....	106
6.3	AccuraGen Inc.	107
6.4	Adaptive Biotechnologies.....	108
6.5	Aethlon Medical	109
6.6	Agilent/Dako	110
6.7	Anchor Dx.....	112
6.8	ANGLE plc.....	113
6.9	ARUP Laboratories.....	114
6.10	AVIVA Systems Biology.....	116
6.11	Baylor Miraca Genetics Laboratories	117
6.12	Beckman Coulter Diagnostics.....	118
6.13	Becton, Dickinson and Company	119
6.14	BGI Genomics Co. Ltd	121
6.15	BillionToOne	123
6.16	Bioarray Genetics.....	124
6.17	Biocartis.....	125
6.18	Biocept, Inc.....	126
6.19	Biodesix Inc.	127
6.20	BioFluidica.....	128
6.21	BioGenex	129
6.22	BioIVT	130
6.23	Biolidics Ltd.....	131
6.24	bioMérieux Diagnostics.....	132
6.25	Bioneer Corporation	134
6.26	Bio-Rad Laboratories, Inc.....	135
6.27	Bio-Reference Laboratories.....	137

6.28	Bio-Techne	138
6.29	Bioview	139
6.30	Bolidics	140
6.31	Boreal Genomics.....	141
6.32	Bristol-Myers Squibb.....	142
6.33	Burning Rock.....	143
6.34	Cardiff Oncology	144
6.35	Caris Molecular Diagnostics	145
6.36	Castle Biosciences, Inc.	146
6.37	Celemics	147
6.38	CellCarta	148
6.39	CellMax Life	149
6.40	Cepheid (Danaher)	150
6.41	Charles River Laboratories.....	152
6.42	Circulogene.....	153
6.43	Cizzle Biotech	154
6.44	Clinical Genomics	155
6.45	Cytolumina Technologies Corp.	156
6.46	Datar Cancer Genetics Limited.....	157
6.47	Diagnologix LLC.....	158
6.48	Diasorin S.p.A.....	159
6.49	Dxcover.....	161
6.50	Enzo Biochem	162
6.51	Epic Sciences.....	163
6.52	Epigenomics AG.....	164
6.53	Eurofins Scientific	165
6.54	Exact Sciences	167
6.55	Fabric Genomics	168

6.56	Fluxion Biosciences.....	169
6.57	Freenome.....	170
6.58	FUJIFILM Wako Diagnostics.....	171
6.59	Fulgent Genetics	172
6.60	Fyr Diagnostics.....	173
6.61	GeneFirst Ltd.	174
6.62	Genetron Holdings	175
6.63	GenomOncology.....	176
6.64	GILUPI Nanomedizin.....	177
6.65	Guardant Health	178
6.66	HansaBiomed	179
6.67	HeiScreen.....	180
6.68	Helomics.....	181
6.69	HTG Molecular Diagnostics	182
6.70	iCellate.....	183
6.71	ICON PLC	184
6.72	Illumina	185
6.73	Incell Dx.....	186
6.74	Inivata	187
6.75	INOVIQ	188
6.76	Integrated Diagnostics	189
6.77	Invitae Corporation.....	190
6.78	Invivogen	191
6.79	Invivoscribe.....	192
6.80	Janssen Diagnostics	193
6.81	Lunglife AI Inc	194
6.82	MDNA Life SCIENCES, Inc.....	195
6.83	MDx Health	196

6.84	Menarini Silicon Biosystems.....	197
6.85	Mesa Laboratories, Inc.	198
6.86	Millipore Sigma	199
6.87	Miltenyi Biotec	200
6.88	miR Scientific.....	201
6.89	Myriad Genetics/Myriad RBM	202
6.90	NantHealth, Inc.	203
6.91	Natera	204
6.92	NeoGenomics	205
6.93	NGeneBio.....	206
6.94	Novogene Bioinformatics Technology Co., Ltd.....	208
6.95	Oncocyte.....	210
6.96	OncoDNA	211
6.97	Ortho Clinical Diagnostics	212
6.98	Oxford Nanopore Technologies	213
6.99	PamGene	214
6.100	Panagene.....	215
6.101	Perkin Elmer.....	216
6.102	Personal Genome Diagnostics.....	217
6.103	Personalis.....	218
6.104	Precipio	219
6.105	Precision Medicine Group	220
6.106	PrecisionMed	221
6.107	Predicine	222
6.108	Promega	223
6.109	Qiagen	225
6.110	Rarecells SAS.....	227
6.111	RareCyte.....	228

6.112	Roche Molecular Diagnostics	229
6.113	ScreenCell	231
6.114	Sema4 Holdings	232
6.115	Sense Biodetection	233
6.116	Siemens Healthineers	234
6.117	simfo GmbH	235
6.118	Singlera Genomics Inc.	236
6.119	Singulomics	237
6.120	SkylineDx	238
6.121	Standard BioTools	239
6.122	Sysmex Inostics	240
6.123	Tempus Labs, Inc.	241
6.124	Thermo Fisher Scientific Inc.	242
6.125	Todos Medical	244
6.126	Varietyx	245
6.127	Veracyte	246
6.128	Volition	247
6.129	Vortex Biosciences	248
6.130	Vyant Bio	249
6.131	Zhejiang Orient Gene Biotech	250
7	The Global Market for MDx Cancer	251
7.1	MDx Cancer – Global Market Overview by Country	252
7.1.1	Table – Global Market by Country	252
7.1.2	Chart - Global Market by Country	253
7.2	Global Market by Cancer Type - Overview	254
7.2.1	Table – Global Market by Cancer Type	254
7.2.2	Chart – Global Market by Cancer Type – Base/Final Comparison	255
7.2.3	Chart – Global Market by Cancer Type – Base Year	256

7.2.4	Chart – Global Market by Cancer Type –Final Year.....	257
7.2.5	Chart – Global Market by Cancer Type – Share by Year	258
7.2.6	Chart – Global Market by Cancer Type – Segment Growth	259
7.3	Global Market by Product Type - Overview	260
7.3.1	Table – Global Market by Product Type.....	260
7.3.2	Chart – Global Market by Product Type – Base/Final Comparison	261
7.3.3	Chart – Global Market by Product Type – Base Year.....	262
7.3.4	Chart – Global Market by Product Type –Final Year	263
7.3.5	Chart – Global Market by Product Type – Share by Year.....	264
7.3.6	Chart – Global Market by Product Type – Segment Growth.....	265
7.4	Global Market by Place - Overview	266
7.4.1	Table – Global Market by Place.....	266
7.4.2	Chart – Global Market by Place – Base/Final Comparison	267
7.4.3	Chart – Global Market by Place – Base Year.....	268
7.4.4	Chart – Global Market by Place –Final Year.....	269
7.4.5	Chart – Global Market by Place – Share by Year.....	270
7.4.6	Chart – Global Market by Place – Segment Growth	271
8	Global Market by Cancer Type	272
8.1	MDx Breast Cancer	273
8.1.1	Table Breast Cancer Testing – by Country	273
8.1.2	Chart - Breast Cancer Testing Growth.....	274
8.2	MDx Colorectal Cancer	275
8.2.1	Table Colorectal Cancer Testing – by Country.....	275
8.2.2	Chart - Colorectal Cancer Testing Growth.....	276
8.3	MDx Cervical Cancer	277
8.3.1	Table Cervical Cancer Testing – by Country	277
8.3.2	Chart - Cervical Cancer Testing Growth.....	278
8.4	MDx Lung Cancer.....	279

8.4.1	Table Lung Cancer Testing – by Country	279
8.4.2	Chart - Lung Cancer Testing Growth.....	280
8.5	MDx Prostate	281
8.5.1	Table Prostate Testing – by Country.....	281
8.5.2	Chart - Prostate Testing Growth	282
8.6	MDx Melanoma Cancer	283
8.6.1	Table Melanoma Cancer Testing – by Country.....	283
8.6.2	Chart - Melanoma Cancer Testing Growth	284
8.7	MDx Blood.....	285
8.7.1	Table Blood Testing – by Country.....	285
8.7.2	Chart - Blood Testing Growth	286
8.8	MDx Companion Dx Development.....	287
8.8.1	Table Companion Dx Development – by Country.....	287
8.8.2	Chart - Companion Dx Development Growth	288
8.9	MDx Other Cancer	289
8.9.1	Table Other Cancer Testing – by Country.....	289
8.9.2	Chart - Other Cancer Testing Growth	290
9	Global Market by Product Type.....	291
9.1	MDx Instruments	292
9.1.1	Table Instruments – by Country	292
9.1.2	Chart - Instruments Growth.....	293
9.2	MDx Reagents	294
9.2.1	Table Reagents – by Country	294
9.2.2	Chart - Reagents Growth	295
9.3	MDx Software and Services.....	296
9.3.1	Table Software and Services – by Country.....	296
9.3.2	Chart - Software and Services Growth.....	297
10	Global Market by Place	298

10.1	MDx Clinical Laboratory	299
10.1.1	Table Clinical Laboratory – by Country	299
10.1.2	Chart - Clinical Laboratory Growth	300
10.2	MDx Pharmaceutical	301
10.2.1	Table Pharmaceutical – by Country	301
10.2.2	Chart - Pharmaceutical Growth	302
10.3	MDx Research	302
10.3.1	Table Research – by Country	303
10.3.2	Chart - Research Growth.....	304
11	Cancer Treatment and Trials.....	305
11.1	FDA Cancer Drug Approvals by Year.....	306
11.2	Clinical Trials Started 2010 to 2016	307
11.3	Prevalence of Cancer Treatments – 2015.....	308
12	Appendices	309
12.1	United States Medicare System: 2022 Clinical Laboratory Fees Schedule.....	309
12.2	FDA Approved Human Genetic Tests.....	395
12.3	FDA Approved Microbial Tests	400
12.4	FDA Approved Pharmacogenomics Tests	409

Table of Tables

Table 2 Clinical Laboratory Departments and Segments	37
Table 3 Laboratory Management Focus – Different Approaches	38
Table 4 Key Segmentation Variables Going Forward.....	39
Table 5 Five Factors Driving Growth	44
Table 6 Factors Limiting Growth	48
Table 8 Seven Key Diagnostic Laboratory Technology Trends	50
Table 8 Global MDx Cancer Market by Region.....	252
Table 9 Global Market by Cancer Type	254
Table 10 Global Market by Product Type	260
Table 11 Global Market by Place.....	266
Table 12 MDx Breast Cancer by Country	273
Table 13 MDx Colorectal Cancer by Country.....	275
Table 14 Cervical Cancer Testing by Country	277
Table 15 Lung Cancer Testing by Country	279
Table 16 Prostate Testing by Country.....	281
Table 17 Melanoma Cancer Testing by Country	283
Table 18 MDx Blood by Country	285
Table 19 MDx Companion Dx Development by Country	287
Table 20 MDx Other Cancer Testing by Country	289
Table 21 MDx Instruments by Country.....	292
Table 22 MDx Reagents by Country.....	294
Table 23 Software and Services by Country.....	296
Table 24 MDx Clinical Laboratory by Country.....	299
Table 25 MDx Pharmaceutical by Country	301
Table 26 Research by Country	303

Table 27 2022 Clinical Lab Fee Schedule 309

Table of Figures

Figure 1 Global Healthcare Spending	33
Figure 2 The Lab Test Pie	35
Figure 4 Population by Age Group	46
Figure 5 Health Care Consumption by Age	46
Figure 6 Cancer Incidence - Age at Diagnosis.....	47
Figure 1 Centralized vs. Decentralized Laboratory Service	51
Figure 2 A Highly Multiplexed Syndromic Testing Unit.....	51
Figure 3 The Real Cost to Sequence the Human Genome.....	53
Figure 4 The Codevelopment Process	55
Figure 7 Comparing MDx Diagnostic and Traditional Testing.....	56
Figure 12 Global Market Shares Base Year.....	253
Figure 13 MDx Market by Cancer - Base vs. Final	255
Figure 14 Cancer Market Base Year	256
Figure 15 Cancer Market Final Year.....	257
Figure 16 MDx Cancer Share by Year	258
Figure 17 MDx Cancer Segment Growth Rates	259
Figure 18 MDx Market by Product - Base vs. Final.....	261
Figure 19 Product Market Base Year	262
Figure 20 Product Market Final Year	263
Figure 21 MDx Product Share by Year	264
Figure 22 MDx Product Segment Growth Rates.....	265
Figure 23 MDx Market by Place - Base vs. Final.....	267
Figure 24 Place Market Base Year.....	268
Figure 25 Place Market Final Year	269
Figure 26 MDx Place Share by Year	270

Figure 27 MDx Place Segment Growth Rates	271
Figure 28 Breast Cancer Testing Growth.....	274
Figure 29 Colorectal Cancer Testing Growth.....	276
Figure 30 Cervical Cancer Testing Growth.....	278
Figure 31 Lung Cancer Testing Growth.....	280
Figure 32 Prostate Testing Growth	282
Figure 33 Melanoma Cancer Testing Growth	284
Figure 34 Blood Testing Growth	286
Figure 35 Companion Dx Development Growth	288
Figure 36 Other Cancer Testing Growth	290
Figure 37 Instruments Growth	293
Figure 38 Reagents Growth	295
Figure 39 Software and Services Growth.....	297
Figure 40 Clinical Laboratory Growth	300
Figure 41 Pharmaceutical Growth	302
Figure 42 Research Growth.....	304
Figure 43 FDA Cancer Drug Approvals by Year.....	306
Figure 44 Clinical Trials for Immunotherapy by Year	307
Figure 45 Pie Chart of Prevalence of Cancer Treatments	308

1 Market Guides